Clinical Trial Update: 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating 3D1002 in combination with oxycodone extended-release for moderate to severe cancer pain; study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Pain

Drugs mentioned

• 3D1002
• oxycodone hydrochloride sustained-release tablets (oxycodone)

Snippet

Sponsor: 3D Medicines | Conditions: Cancer Pain | Phase 2 | Status: NOT_YET_RECRUITING